MedTrace Logo

Study of Gamma PN3 in the Elderly

NCT06562790 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2025-05-11

No results posted yet for this study

Summary

Phase 1 double- blind randomised active comparator dose escalating study of Gamma PN3 in the elderly

Conditions

  • Pneumonia, Pneumococcal

Interventions

BIOLOGICAL

Gamma PN3

500, 1000 or 1500 µg by IM injection on Days 1 and 29

BIOLOGICAL

Prevnar

1 dose on Day 1 and saline placebo on Day 29

Sponsors & Collaborators

  • GPN Vaccines

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-26
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06562790 on ClinicalTrials.gov